Pharmacologic Determinants for Optimized Therapy in HIV-Infected Children

HIV 感染儿童优化治疗的药理学决定因素

基本信息

项目摘要

DESCRIPTION (provided by applicant): With a long-term career goal of designing and executing pediatric clinical drug trials focused on understanding the pharmacology of infectious disease therapies, I seek support in my career development through this Mentored Patient-Oriented Research Career Development Award (K23). With the completion of my Pediatric Infectious Diseases fellowship in June 2007, this career development plan will provide me with the necessary components for an independent physician-scientist career path at the interface between pediatric infectious diseases and pharmacology via the following: (1) formal education in pediatric pharmacology and clinical trials design, including advanced coursework in pharmacology, pharmacology seminars and journal clubs, training in the responsible conduct of research, and a Masters degree in Clinical Research at the University of California, San Diego (UCSD), (2) research training in population pharmacologic modeling, simulation, and clinical pharmacology analysis techniques at UCSD's Pediatric Pharmacology Research Unit (PPRU) and UCSD's International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) group laboratory, and (3) a structured plan for publications, presentations, and mentoring oversight. This proposal is feasible because of the sound career development and research plans as well as the strong support from my mentors, advisory committee, and the Department of Pediatrics at UCSD. Despite the worldwide use of antiretrovirals in HIV-infected children, little pharmacologic data exists to determine whether the current dosing regimens are optimal. Under the guidance of Dr. Capparelli, Director of UCSD's PPRU and Dr. Spector, Director of UCSD's Mother Child Adolescent HIV Program, I will focus my research on the pharmacologic determinants that affect the pharmacokinetics and pharmacodynamics of lamivudine, zidovudine, and diagnosing in HIV-infected children. By simulating the effects of the population models developed in this proposal, we will determine whether the current dosing regimens provide optimal plasma concentrations. These data are important for the health of children worldwide as our data will provide novel, critical pharmacologic information about antiretrovirals in children and ensure that current guidelines provide optimal dosing for HIV-infected children across a wide age range.
描述(由申请人提供):以长期的职业目标设计和执行儿科临床药物试验,重点是了解传染病疗法的药理学,我通过这项受过指导的以患者为导向的研究职业发展奖(K23)在我的职业发展中寻求支持。 With the completion of my Pediatric Infectious Diseases fellowship in June 2007, this career development plan will provide me with the necessary components for an independent physician-scientist career path at the interface between pediatric infectious diseases and pharmacology via the following: (1) formal education in pediatric pharmacology and clinical trials design, including advanced coursework in pharmacology, pharmacology seminars and journal clubs, training in the responsible conduct of研究,以及加州大学圣地亚哥分校(UCSD)的临床研究硕士学位,(2)在UCSD的儿科药理学研究单元(PPRU)和UCSD的国际孕产妇辅助效力(IMPA)组合(IMPA)组成(IMPA),演讲和指导监督。该提案是可行的,因为合理的职业发展和研究计划以及我的导师,咨询委员会和UCSD儿科部的大力支持。尽管全球抗逆转录病毒在HIV感染的儿童中使用了抗逆转录病毒,但很少有药理学数据可以确定当前的剂量方案是否最佳。在UCSD的PPRU主任Capparelli博士和UCSD母童青少年艾滋病毒计划主任Spector博士的指导下,我将重点关注我的研究上,这些决定因素会影响兰米夫定,Zidovudine,Zidovudine和HIV受HIV侵害儿童的药代动力学和药态动力学的药理决定因素。通过模拟本提案中开发的种群模型的影响,我们将确定当前的给药方案是否提供最佳的血浆浓度。这些数据对于全球儿童的健康很重要,因为我们的数据将提供有关儿童抗逆转录病毒病的新颖,关键的药理信息,并确保当前的准则为跨年龄范围内的HIV感染儿童提供最佳剂量。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ADRIANA H TREMOULET其他文献

ADRIANA H TREMOULET的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ADRIANA H TREMOULET', 18)}}的其他基金

Optimization of Antibiotics in Mothers and their Breastfed Infants Using Pharmacomicrobiomic and Metabolomic Analyses (mPRINT P50)
使用药物微生物组学和代谢组学分析优化母亲及其母乳喂养婴儿的抗生素 (mPRINT P50)
  • 批准号:
    10487509
  • 财政年份:
    2021
  • 资助金额:
    $ 12.18万
  • 项目类别:
Optimization of Antibiotics in Mothers and their Breastfed Infants Using Pharmacomicrobiomic and Metabolomic Analyses (mPRINT P50)
使用药物微生物组学和代谢组学分析优化母亲及其母乳喂养婴儿的抗生素 (mPRINT P50)
  • 批准号:
    10309712
  • 财政年份:
    2021
  • 资助金额:
    $ 12.18万
  • 项目类别:
Optimization of Antibiotics in Mothers and their Breastfed Infants Using Pharmacomicrobiomic and Metabolomic Analyses (mPRINT P50)
使用药物微生物组学和代谢组学分析优化母亲及其母乳喂养婴儿的抗生素 (mPRINT P50)
  • 批准号:
    10681302
  • 财政年份:
    2021
  • 资助金额:
    $ 12.18万
  • 项目类别:
Phase I and IIa trial of atorvastatin in children with acute Kawasaki disease
阿托伐他汀治疗急性川崎病儿童的 I 期和 IIa 期试验
  • 批准号:
    9096853
  • 财政年份:
    2014
  • 资助金额:
    $ 12.18万
  • 项目类别:
Phase I and IIa trial of atorvastatin in children with acute Kawasaki disease
阿托伐他汀治疗急性川崎病儿童的 I 期和 IIa 期试验
  • 批准号:
    9216033
  • 财政年份:
    2014
  • 资助金额:
    $ 12.18万
  • 项目类别:
Pharmacologic Determinants for Optimized Therapy in HIV-Infected Children
HIV 感染儿童优化治疗的药理学决定因素
  • 批准号:
    8123189
  • 财政年份:
    2007
  • 资助金额:
    $ 12.18万
  • 项目类别:
Pharmacologic Determinants for Optimized Therapy in HIV-Infected Children
HIV 感染儿童优化治疗的药理学决定因素
  • 批准号:
    7490096
  • 财政年份:
    2007
  • 资助金额:
    $ 12.18万
  • 项目类别:
Pharmacologic Determinants for Optimized Therapy in HIV-Infected Children
HIV 感染儿童优化治疗的药理学决定因素
  • 批准号:
    7673722
  • 财政年份:
    2007
  • 资助金额:
    $ 12.18万
  • 项目类别:
Pharmacologic Determinants for Optimized Therapy in HIV-Infected Children
HIV 感染儿童优化治疗的药理学决定因素
  • 批准号:
    7908694
  • 财政年份:
    2007
  • 资助金额:
    $ 12.18万
  • 项目类别:
Pediatric and Developmental Pharmacology for Inflammatory and Infectious Diseases
炎症和传染病的儿科和发育药理学
  • 批准号:
    9355662
  • 财政年份:
  • 资助金额:
    $ 12.18万
  • 项目类别:

相似国自然基金

坚持还是转型?反馈驱动的创业者机会信念认知更新及响应决策机理
  • 批准号:
  • 批准年份:
    2022
  • 资助金额:
    45 万元
  • 项目类别:
    面上项目
坚持还是转型?反馈驱动的创业者机会信念认知更新及响应决策机理
  • 批准号:
    72272131
  • 批准年份:
    2022
  • 资助金额:
    45.00 万元
  • 项目类别:
    面上项目
不确定性下创业团队能量和抗逆力对创业坚持的权变影响研究
  • 批准号:
    72162025
  • 批准年份:
    2021
  • 资助金额:
    29 万元
  • 项目类别:
    地区科学基金项目
创造性思维中灵活性和坚持性动态交互的神经基础
  • 批准号:
  • 批准年份:
    2021
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
创造性思维中灵活性和坚持性动态交互的神经基础
  • 批准号:
    32100850
  • 批准年份:
    2021
  • 资助金额:
    24.00 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

RP3 PrEP Choice
RP3 PrEP 选择
  • 批准号:
    10595903
  • 财政年份:
    2023
  • 资助金额:
    $ 12.18万
  • 项目类别:
Screen Smart: Using Digital Health to Improve HIV Screening and Prevention for Adolescents in the Emergency Department
智能屏幕:利用数字健康改善急诊科青少年的艾滋病毒筛查和预防
  • 批准号:
    10711679
  • 财政年份:
    2023
  • 资助金额:
    $ 12.18万
  • 项目类别:
Identifying socioecological profiles that impact changes in care outcomes among Black Sexual minority men living with HIV
确定影响感染艾滋病毒的黑人性少数男性护理结果变化的社会生态特征
  • 批准号:
    10675256
  • 财政年份:
    2023
  • 资助金额:
    $ 12.18万
  • 项目类别:
RP1 Screen 2 Prevent
RP1 屏蔽 2 预防
  • 批准号:
    10595901
  • 财政年份:
    2023
  • 资助金额:
    $ 12.18万
  • 项目类别:
International Workshops on HIV Pediatrics
国际艾滋病儿科研讨会
  • 批准号:
    10548045
  • 财政年份:
    2022
  • 资助金额:
    $ 12.18万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了